Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced ...

Japanese drugmaker Eisai Inc. will lay off 57 employees in Nutley between the end of March and May, public records show, as the pharmaceutical company shaves off 7% of its U.S workforce.

HHS Secretary Robert F. Kennedy Jr. is proposing to strip public participation from much of the business his agency conducts ...

Leqembi’s application now moves forward to the European Commission, which will issue a formal verdict for the injection that ...

Eisai (ESAIY) and Biogen (BIIB) announced that the Therapeutic Goods Administration, TGA, of Australia has confirmed the initial decision to ...

The European Union’s medicines regulator on Friday reiterated its positive recommendation for Eisai and Biogen’s Alzheimer’s ...

Health updates cover U.S. involvement in WHO meetings, UK approval of Moderna's RSV vaccine, a Texas measles outbreak, FDA ...

Along with Nutley-based Eisai, several other New Jersey-based giants in the space have conducted layoffs over the past few ...

SciClone will develop and distribute Tasfygo in greater China but Eisai will retain worldwide rights outside the region.

The European Commission had requested the committee consider new data on the drug that became available after it had adopted its positive opinion.

The European Union's medicines regulator on Friday reiterated its positive recommendation for Eisai and Biogen's Alzheimer's ...

Eisai will maintain the rights to tasurgratinib worldwide outside of the licensed regions.